A Registry for Patients With Chronic Hypoparathyroidism
This is a prospective, observational disease and drug registry designed to evaluate the safety and effectiveness profile of rhPTH(1-84) under conditions of routine clinical practice and to observe the clinical course of chronic hypoparathyrodism. No treatment is provided as a result of participating in this registry and all decisions on the participant's treatment are determined by his or her physician.
- Chronic Hypoparathyroidism
- Eligible Ages
- All ages
- Eligible Genders
- Accepts Healthy Volunteers
- Participants diagnosed with chronic hypoparathyroidism, ie, hypoparathyroidism with a duration of longer than 6 months, including:
- Adult participants (greater than or equal to [>=] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.
- Pediatric participants (less than [<] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.
- Participants or legally acceptable representatives unable to provide informed consent.
- Participants using rhPTH(1-34) or used rhPTH(1-34) for more than 2 years and in the last 3 months. FOR US SITES ONLY: Participants treated with rhPTH(1-84) prior to the US recall may use rhPTH(1-34) only while rhPTH(1-84) is unavailable due to the recall.
- Participants currently enrolled in an interventional clinical study (whether or not the study is related to hypoparathyroidism). Note that this does not include participants enrolled in other observational registries.
- History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism).
- Study Type
- Observational [Patient Registry]
- Observational Model
- Time Perspective
|Chronic Hypoparathyroidism||A rare disease with a duration of longer than 6 months characterized by insufficient parathyroid hormone (PTH) secretion, which can result in hypocalcemia, hyperphosphatemia, and associated clinical findings.||
Study ContactShire Contact